1
2
3
We don't have analytics for this instrument yet. You can contribute!
Please log in and be the first author to write an article about this instrument!
Minerva Neurosciences, Inc. (NASDAQ)
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Horario de operaciones (UTC)
Abrir ahora
Cerrado
Cierre el
Apertura el
a las
-
El horario de apertura del mercado se indica según su zona horaria local
(UTC)
Ticker | NERV |
Valor de contrato | 100 shares |
Apalancamiento máximo | 1:5 |
Historial de swaps
Fecha | Short Swap (%) | Long Swap (%) | No hay datos |
---|
Volumen mínimo de una transacción | 0.01 lotes |
Volumen máximo de una transacción | 100 lotes |
Margen de cobertura | 50% |